molecular
techniqu
identifi
detect
microorgan
clinic
microbiolog
laboratori
becom
routin
question
cost
techniqu
contribut
patient
care
need
address
molecular
diagnosi
appropri
infecti
agent
difficult
detect
identifi
test
suscept
time
fashion
convent
method
last
year
detect
infecti
diseas
agent
begun
includ
use
nucleic
acidbas
technolog
diagnosi
infect
caus
parasit
organ
last
field
clinic
microbiolog
incorpor
techniqu
molecular
techniqu
eg
pcr
hybrid
assay
recent
develop
detect
speci
differenti
phylogenet
analysi
use
detect
infecti
agent
clinic
diagnost
laboratori
vaneechoutt
van
elder
although
mainli
research
tool
nucleic
acid
sequenc
analysi
coupl
target
amplif
clinic
use
help
detect
identifi
previous
uncultiv
organ
character
antimicrobi
resist
gene
mutat
thu
aid
diagnosi
treatment
infecti
diseas
autom
highdens
oligonucleotid
probe
array
dna
chip
also
hold
great
promis
character
microbi
pathogen
although
clinician
microbiologist
enthusiast
welcom
new
molecular
test
diagnos
infecti
diseas
high
cost
test
concern
despit
probabl
improv
patient
outcom
reduc
cost
antimicrobi
agent
length
hospit
stay
outweigh
increas
laboratori
cost
incur
use
molecular
test
save
difficult
document
past
sever
year
develop
applic
molecular
diagnost
techniqu
initi
revolut
diagnosi
monitor
infecti
diseas
technolog
advanc
diagnost
test
continu
improv
year
present
new
altern
standard
procedur
given
plethora
diagnost
altern
diagnost
test
must
evalu
determin
place
diagnost
armamentarium
criteria
includ
sensit
specif
posit
neg
predict
valu
likelihood
ratio
posit
neg
test
receiv
oper
characterist
curv
preval
diseas
influenc
diagnost
util
test
particularli
diseas
rare
frequent
fardi
microbi
phenotyp
characterist
protein
bacteriophag
chromatograph
profil
well
biotyp
suscept
test
use
routin
laboratori
identif
differenti
nucleic
acid
techniqu
plasmid
profil
variou
method
gener
restrict
fragment
length
polymorph
polymeras
chain
reaction
make
increas
inroad
clinic
laboratori
wagar
pcrbase
system
detect
etiolog
agent
diseas
directli
clinic
sampl
without
need
cultur
use
rapid
detect
uncultur
fastidi
microorgan
schluger
et
al
addit
sequenc
analysi
amplifi
microbi
dna
allow
identif
better
character
pathogen
subspeci
variat
identifi
variou
techniqu
shown
import
prognosi
certain
diseas
import
advanc
includ
determin
viral
load
direct
detect
gene
gene
mutat
respons
drug
resist
increas
use
autom
userfriendli
softwar
make
technolog
wide
avail
detect
infecti
agent
nucleic
acid
level
repres
true
synthesi
clinic
chemistri
clinic
microbiolog
techniqu
tang
et
al
commerci
kit
contain
nonisotop
label
nucleic
acid
probe
avail
direct
detect
pathogen
clinic
materi
identif
organ
isol
cultur
tabl
use
solutionphas
hybrid
allow
test
perform
singli
batch
familiar
microwel
format
although
direct
detect
organ
clinic
specimen
nucleic
acid
probe
rapid
simpl
suffer
lack
sensit
direct
probe
detect
assay
requir
least
copi
nucleic
acid
per
microlit
reliabl
detect
requir
rare
met
clinic
sampl
without
form
amplif
amplif
detect
signal
probe
hybrid
improv
sensit
low
gene
copi
per
microlit
provid
quantit
capabl
approach
use
extens
quantit
assay
viral
load
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
tabl
match
analyt
sensit
target
amplificationbas
method
polymeras
chain
reaction
detect
organ
commerci
probe
system
use
solutionphas
hybrid
chemiluminesc
direct
detect
infecti
agent
clinic
materi
includ
product
genprob
hybrid
captur
assay
system
digen
murex
tabl
system
user
friendli
long
shelf
life
adapt
small
larg
number
specimen
product
design
direct
detect
neisseria
gonorrhoea
chlamydia
trachomati
singl
specimen
one
specimen
two
separ
probe
hybrid
captur
system
detect
human
papilloma
viru
hpv
cervic
scrape
ciotti
et
al
herp
simplex
viru
hsv
vesicl
materi
cytomegaloviru
cmv
blood
fluid
cinqu
et
al
test
demonstr
sensit
exceed
cultur
immunolog
method
detect
respect
pathogen
less
sensit
pcr
target
amplificationbas
method
signal
amplificationbas
probe
method
detect
quantit
virus
hbv
hcv
hiv
present
enzym
immunoassaylik
format
includ
branch
chain
dna
probe
chiron
qb
replicas
genetrak
method
tabl
method
sensit
target
amplificationbas
method
detect
virus
howev
quantit
result
proven
use
determin
viral
load
prognosi
monitor
respons
therapi
probe
hybrid
use
identifi
slowgrow
organ
isol
cultur
use
either
liquid
solid
media
identif
mycobacteria
slowgrow
organ
dimorph
fungi
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
certainli
facilit
commerci
avail
probe
commerci
probe
identifi
organ
produc
genprob
use
acridinium
esterlabel
probe
direct
speciesspecif
rrna
sequenc
tabl
genprob
product
avail
cultur
identif
mycobacterium
tuberculosi
aviumintracellular
complex
gordona
kansasii
cryptococcu
neoforman
dimorph
fungi
n
gonorrhoea
staphylococcu
aureu
streptococcu
pneumonia
escherichia
coli
haemophilu
influenza
enterococcu
spp
agalactia
listeria
monocytogen
sensit
specif
probe
excel
provid
speci
identif
within
one
work
day
bacteria
list
plu
c
neoforman
easili
effici
identifi
convent
method
within
day
mani
probe
wide
use
mycobacteri
probe
hand
accept
mainstay
identif
tuberculosi
relat
speci
nucleic
acid
amplif
provid
abil
select
amplifi
specif
target
present
low
concentr
detect
level
thu
amplificationbas
method
offer
superior
perform
term
sensit
direct
nonamplifi
probebas
test
pcr
roch
molecular
system
branchburg
nj
first
techniqu
develop
flexibl
eas
perform
remain
wide
use
molecular
diagnost
techniqu
research
clinic
laboratori
sever
differ
amplificationbas
strategi
develop
avail
commerci
tabl
commerci
amplificationbas
molecular
diagnost
system
infecti
diseas
focus
larg
system
detect
n
gonorrhoea
c
trachomati
tuberculosi
specif
viral
infect
hbv
hcv
hiv
cmv
enteroviru
tabl
given
adapt
pcr
numer
addit
infecti
pathogen
detect
investigatordevelop
pcr
assay
tabl
mani
instanc
test
provid
import
clinic
relev
inform
would
otherwis
unavail
sinc
commerci
interest
slow
expand
line
product
avail
clinic
laboratori
addit
qualit
detect
virus
quantit
viral
load
clinic
specimen
recogn
great
import
diagnosi
prognosi
therapeut
monitor
hcv
hiv
hbv
cmv
pcr
nucleic
acid
strandbas
amplif
system
avail
quantit
one
virus
adapt
amplificationbas
test
method
commerci
avail
kit
serv
optim
user
accept
prevent
contamin
standard
reagent
test
condit
make
autom
possibl
clear
extent
level
detect
achiev
differ
amplif
strategi
differ
none
newer
method
provid
level
sensit
greater
pcr
choos
molecular
diagnost
system
one
consid
rang
test
avail
suitabl
method
workflow
cost
choos
one
amplificationbas
method
provid
test
capabl
sever
pathogen
certainli
practic
amplificationbas
method
also
valuabl
identifi
cultur
noncultivat
organ
amplif
reaction
may
design
rapidli
identifi
acidfast
organ
tuberculosi
may
amplifi
genusspecif
univers
target
character
use
restrict
endonucleas
digest
hybrid
multipl
probe
sequenc
determin
provid
speci
even
subspeci
delin
although
identif
initi
appli
slowgrow
mycobacteria
applic
pathogen
difficult
imposs
identifi
convent
method
molecular
method
rapidli
detect
antimicrobialdrug
resist
clinic
set
substanti
contribut
understand
spread
genet
resist
convent
brothand
agarbas
antimicrobi
suscept
test
method
provid
phenotyp
profil
respons
given
microb
array
agent
although
use
select
potenti
use
therapeut
agent
convent
method
slow
fraught
problem
common
fail
detect
methicillin
resist
staphylococci
may
express
heterogen
fashion
make
phenotyp
character
resist
difficult
current
molecular
detect
resist
gene
mec
standard
phenotyp
method
detect
methicillin
resist
judg
molecular
method
may
use
detect
specif
antimicrobialdrug
resist
gene
resist
genotyp
mani
organ
tabl
detect
specif
point
mutat
associ
resist
antivir
agent
also
increasingli
import
screen
mutat
amplifi
product
may
facilit
use
highdens
probe
array
gene
chip
despit
mani
potenti
advantag
genotyp
like
replac
phenotyp
method
detect
antimicrobialdrug
resist
clinic
laboratori
near
futur
molecular
method
resist
detect
tabl
may
appli
directli
clinic
specimen
provid
simultan
detect
identif
pathogen
plu
resist
character
likewis
use
detect
resist
virus
slowgrow
nonviabl
organ
organ
resist
mechan
reliabl
detect
phenotyp
method
howev
high
specif
molecular
method
detect
newli
emerg
resist
mechan
unlik
use
detect
resist
gene
speci
gene
observ
previous
furthermor
presenc
resist
gene
mean
gene
express
absenc
known
resist
gene
exclud
possibl
resist
anoth
mechan
phenotyp
antimicrobi
suscept
test
method
allow
laboratori
test
mani
organ
detect
newli
emerg
well
establish
resist
pattern
b
meca
encod
alter
penicillin
bind
protein
phenotyp
method
may
requir
h
incub
detect
resist
less
sensit
detect
meca
potenti
clinic
applic
specif
circumst
c
vancomycin
resist
enterococci
may
relat
one
four
distinct
resist
genotyp
vana
vanb
import
genotyp
detect
resist
use
valid
phenotyp
method
genet
basi
resist
betalactam
antibiot
extrem
complex
bla
tem
bla
shv
gene
two
common
set
plasmid
encod
betalactamas
presenc
either
bla
tem
bla
shv
gene
impli
ampicillin
resist
variant
bla
tem
bla
shv
gene
extend
spectrum
betalactamas
may
also
encod
resist
rang
thirdgener
cephalosporin
monobactam
e
tuberculo
slow
grow
four
week
may
requir
obtain
phenotyp
suscept
test
result
detect
resist
gene
tuberculosi
potenti
clinic
applic
short
term
f
phenotyp
method
suffici
practic
routin
clinic
detect
resist
antivir
agent
genotyp
method
repres
practic
method
routin
detect
antivir
resist
g
abbrevi
defin
text
rflp
restrict
fragment
length
polymorph
sscp
singlestrand
conform
polymorph
lipa
line
probe
assay
tk
thymidin
kinas
rt
revers
transcriptas
prot
proteas
past
year
seen
expans
growth
use
molecular
technolog
clinic
laboratori
diagnos
infecti
diseas
jeffrey
et
al
result
mani
laboratori
abl
offer
sensit
test
faster
turnaround
time
ultim
improv
patient
care
gold
standard
bacteriolog
larg
remain
cultur
primarili
due
cost
account
potenti
complex
natur
associ
infect
ie
urin
wound
respiratori
cultur
howev
circumst
may
minut
quantiti
specif
pathogen
present
patient
may
receiv
antibiot
prior
specimen
collect
etiolog
agent
may
requir
unusu
cultur
condit
molecular
detect
offer
great
advantag
cultur
techniqu
mani
virolog
laboratori
molecular
detect
supplant
cell
cultur
techniqu
identif
sever
viral
pathogen
mani
case
becom
new
gold
standard
though
molecular
techniqu
offer
abund
ad
benefit
use
augment
current
gold
standard
cultur
andor
serolog
optim
use
molecular
methodolog
microbiolog
resid
specimen
limit
number
pathogen
organ
sought
case
enhanc
sensit
faster
turnaround
time
molecular
method
far
outweigh
increas
cost
sexual
transmit
infect
sti
constitut
import
worldwid
public
health
problem
msuya
et
al
use
sensit
specif
laboratori
method
diagnos
condit
crucial
reduc
transmiss
sequela
sti
neisseria
gonorrhoea
chlamydia
trachomati
pathogen
frequent
involv
urethr
cervic
infect
cultur
continu
gold
standard
diagnos
gonorrhea
nucleic
acid
amplif
assay
consid
new
gold
standard
c
trachomati
although
cultur
till
specif
techniqu
genit
ulcer
due
treponema
pallidum
haemophilu
ducreyi
herp
simplex
viru
littl
clinic
bacteriolog
correl
therefor
essenti
establish
microbiolog
diagnosi
lesion
present
primari
secondari
period
syphili
diagnos
dark
field
microscopi
serolog
diagnosi
remain
period
base
nontreponem
test
associ
confirmatori
treponem
test
cell
cultur
consid
gold
standard
herp
simplex
viru
although
molecular
method
also
sensit
specif
near
current
microbiolog
diagnosi
h
ducreyi
vener
lymphogranuloma
achiev
use
molecular
method
sampl
obtain
ulcer
lymph
adenopathi
diagnosi
genit
wart
immunocompet
patient
base
clinic
find
case
lesion
suffici
characterist
cultur
consid
refer
method
trichomona
vaginali
infect
et
al
sever
new
techniqu
diagnosi
sexual
transmit
diseas
develop
past
decad
rapid
noncultur
techniqu
direct
detect
chlamydia
trachomati
neisseria
gonorrhoea
herp
simplex
viru
review
advantag
disadvantag
compar
convent
diagnost
method
wood
polymeras
chain
reaction
test
perform
specimen
consecut
male
patient
genit
ulcer
detect
sexual
transmit
pathogen
pcr
also
perform
detect
neisseria
gonorrhoea
chlamydia
trachomati
trichomona
vaginali
urethr
specimen
consecut
subject
dysuria
urethr
discharg
antibodi
test
syphili
herp
simplex
viru
human
immunodefici
viru
antibodi
perform
men
risk
genit
ulcer
ask
relev
symptom
without
prompt
examin
clinic
maxim
likelihood
correct
diagnosi
treatment
find
high
preval
associ
dysuria
caution
provid
empir
treatment
gonorrhoea
chlamydia
ulcer
patient
dysuria
without
urethr
discharg
innov
strategi
limit
burden
infect
popul
requir
ofarrel
et
al
even
microbiolog
screen
incorpor
sti
control
strategi
lack
access
appropri
servic
especi
rural
remot
area
reluct
atrisk
popul
attend
treatment
fear
invas
genit
examin
lower
sensit
convent
diagnost
assay
reduc
effect
programm
therefor
accur
costeffect
reliabl
diagnost
assay
prefer
use
field
need
impact
incid
variou
sti
well
hiv
advent
molecular
technolog
includ
target
signal
amplif
method
diagnos
sti
revolutionis
allow
use
non
minim
invas
sampl
techniqu
selfcollect
patient
eg
firstvoid
urin
cervicovagin
lavag
low
vagin
swab
tampon
studi
evalu
selfsampl
molecular
diagnost
techniqu
demonstr
equival
superior
detect
sti
compar
convent
sampl
detect
method
sampl
method
also
use
determin
preval
sti
variou
popul
particularli
difficult
access
medic
care
garland
tabrizi
presenc
trichomona
vaginali
tv
associ
increas
risk
coinfect
chlamydia
trachomati
ct
andor
neisseria
gonorrhoea
ng
femal
patient
present
ed
symptom
consist
sexual
transmit
diseas
std
white
et
al
vagin
swab
specimen
choic
screen
chlamydia
trachomati
neisseria
gonorrhoea
result
multicent
evalu
aptima
assay
infect
schachter
et
al
genprob
aptima
combo
food
drug
administrationclear
nucleic
acid
amplif
test
naat
detect
chlamydia
trachomati
neisseria
gonorrhoea
urin
urogenit
swab
specimen
center
diseas
control
prevent
recommend
confirm
posit
naat
result
lowpreval
popul
aptima
ct
act
aptima
gc
agc
two
discret
naat
c
trachomati
n
gonorrhoea
detect
suitabl
confirm
result
target
differ
nucleic
acid
sequenc
thu
act
agc
rel
sensit
compar
aptima
assay
detect
confirm
posit
result
cultur
dfa
lcx
perform
aptima
assay
alter
use
variou
swab
type
longterm
storag
specimen
aptima
assay
highli
sensit
rapid
act
agc
recommend
confirm
posit
result
naat
lcx
boyadzhyan
et
al
lyme
borreliosi
caus
spirochet
borrelia
burgdorferi
common
vector
born
diseas
north
america
europ
asia
multisystem
infect
may
caus
skin
neurolog
cardiac
rheumatolog
disord
use
serolog
test
valu
diagnosi
lyme
diseas
remain
confus
controversi
physician
especi
concern
person
low
risk
diseas
sampl
drawn
patient
within
four
week
diseas
onset
test
western
blot
techniqu
immunoglobulin
immunoglobulin
g
antibodi
sampl
drawn
four
week
diseas
onset
test
immunoglobulin
g
depietropaolo
et
al
current
serolog
lyme
diseas
test
use
whole
borrelia
cell
sourc
antigen
assay
difficult
standard
optim
sensit
specif
recent
introduc
highli
sensit
pcr
methodolog
use
amplif
subsequ
identif
b
burgdorferi
specif
sequenc
diagnost
sensit
pcr
compar
even
higher
vitro
cultur
pcr
significantli
sensit
histolog
b
burgdorferi
specif
immunophosphatasestain
method
sensit
pcr
superior
cultur
serolog
clear
evid
pcr
sensit
specif
test
detect
b
burgdorferi
skin
biopsi
patient
earli
late
dermatoborreliosi
pcr
use
diagnost
aid
patient
howev
gener
measur
specif
intrathec
antibodi
product
patient
neuroborreliosi
superior
pcr
furthermor
strain
differ
import
select
suitabl
antigen
diagnost
assay
vaccin
develop
sinc
b
burgdorferi
isol
studi
phenotyp
genotyp
trait
shown
highli
heterogen
lebech
viral
infect
common
caus
respiratori
tract
diseas
outpati
set
virus
influenza
respiratori
syncyti
viru
rsv
cytomegaloviru
cmv
varicellazost
viru
vzv
rel
common
other
adenoviru
sever
acut
respiratori
syndrom
sar
coronaviru
hantaviru
viral
hemorrhag
fever
vhf
rare
immens
public
health
impact
case
acut
lri
rapid
diagnosi
pathogen
may
import
initi
antivir
therapi
stop
virus
affect
human
throughout
world
current
method
use
diagnosi
infect
rsv
b
influenza
viru
b
cost
treat
children
lri
exceed
million
unit
state
respiratori
syncyti
viru
rsv
type
includ
viru
isol
shell
vial
assay
antigen
detect
serolog
major
limit
techniqu
includ
type
b
influenza
b
virus
human
parainfluenza
viru
hpiv
type
caus
viral
low
sensit
low
specif
prolong
time
complet
infant
elderli
individu
compromis
cardiac
pulmonari
immun
system
greatest
risk
develop
rapid
molecular
techniqu
gene
amplif
eg
pcr
allow
detect
small
risk
seriou
complic
virus
multiplex
quantit
revers
transcriptionpolymeras
chain
reactionenzym
hybrid
assay
hexaplex
prodess
milwauke
develop
use
rapidli
detect
quantit
rna
respiratori
syncyti
virus
b
influenza
virus
b
human
parainfluenza
viru
type
nasal
wash
specimen
singl
test
primer
probe
origin
highli
conserv
region
viral
genom
fan
et
al
pcr
becom
firstlin
diagnost
test
viral
mening
enceph
jefferi
et
al
molecular
biologybas
assay
invalu
tool
manag
chronic
viral
hepat
use
test
blood
donat
diagnos
activ
infect
help
establish
prognosi
guid
treatment
decis
assess
virolog
respons
therapi
pawlotski
human
papilloma
viru
strictli
epitheliotrop
hostspecif
current
differ
type
base
deoxyribonucl
acid
sequenc
rather
serolog
identifi
papilloma
viru
type
infect
skin
other
infect
oral
genit
mucou
membran
human
papilloma
viru
type
often
associ
invas
carcinoma
uterin
cervix
intraepitheli
precursor
variou
techniqu
detect
human
papilloma
viru
may
use
cytolog
electron
microscopi
immunocytochemistri
becom
appar
nucleic
acid
hybrid
reliabl
method
viral
diagnosi
genotyp
morinet
zika
viru
zikv
emerg
mosquitoborn
flaviviru
circul
asia
africa
human
infect
induc
influenzalik
syndrom
associ
retroorbit
pain
oedema
lymphadenopathi
diarrhea
diagnosi
zika
fever
requir
viru
isol
serolog
time
consum
crossreact
onestep
rtpcr
assay
detect
zikv
human
serum
success
report
fay
et
al
detect
viru
genom
mutant
molecular
technolog
essenti
clinic
practic
patient
hepat
b
viru
hbv
hepat
c
viru
hcv
relat
liver
diseas
silva
et
al
multiplex
pcr
mpcr
assay
colorimetr
detect
devis
simultan
amplif
dna
target
haemophilu
ducreyi
treponema
pallidum
herp
simplex
viru
hsv
type
mpcr
assay
sensit
standard
diagnost
test
detect
hsv
h
ducreyi
pallidum
genit
ulcer
orl
et
al
polymeras
chain
reaction
highli
sensit
techniqu
detect
hepat
b
virusdna
hepat
c
virusrna
serum
liver
tissu
peripher
mononuclear
blood
cell
polymeras
chain
reaction
detect
hepat
c
virusrna
serum
may
mean
confirm
acut
hepat
c
infect
also
identifi
viraemia
chronic
diseas
particularli
antihepat
c
viru
antibodyneg
individu
also
use
direct
evalu
mother
child
hepat
c
viru
transmiss
hepat
b
polymeras
chain
reaction
use
monitor
reinfect
hepat
c
viru
liver
transplant
prove
invalu
identif
differ
hepat
c
viru
genotyp
efficaci
antivir
treatment
also
monitor
use
polymeras
chain
reaction
polymeras
chain
reaction
thu
shown
numer
advantag
diseas
detect
monitor
despit
limit
impos
exampl
possibl
contamin
problem
semiquantit
evalu
nest
polymeras
chain
reaction
pcr
evalu
detect
cytomegaloviru
cmv
dna
cerebrospin
fluid
csf
cmv
pcr
csf
highli
sensit
specif
consid
rapid
reliabl
diagnost
method
cmv
infect
central
nervou
system
cinqu
molecular
detect
virus
extend
beyond
standard
therapeut
monitor
viral
load
specif
patient
popul
cell
cultur
techniqu
insensit
due
low
viral
burden
typic
found
associ
enceph
perhap
also
presenc
host
neutral
antibodi
csf
cultur
hsv
detect
less
clinic
determin
adult
hsv
enceph
case
neonat
central
nervou
system
cn
diseas
contrast
hsv
naa
posit
adult
case
result
sensit
specif
sensit
specif
neonat
mening
rapid
diagnosi
hsv
enceph
prevent
brain
biopsi
rapidli
determin
need
acyclovir
therapi
enteroviru
common
caus
asept
mening
summer
fall
month
temper
climat
account
enceph
case
nucleic
acid
amplif
also
success
appli
etiolog
viral
cn
diseas
cmv
varicellazost
viru
vzv
assay
implement
broadli
hsv
ev
still
transit
becom
method
choic
note
enceph
virus
readili
detect
naa
exampl
due
short
period
viremia
mani
carbovir
infect
ie
west
nile
viru
csf
naa
low
sensit
gold
standard
remain
serolog
csf
naa
fals
neg
result
occur
due
collect
csf
earli
late
ill
rapid
viral
clearanc
immunocompet
host
naa
inhibitor
fals
posit
csf
naa
result
also
occur
primarili
due
lack
data
suggest
detect
certain
viral
nucleic
acid
correl
clinic
cn
diseas
also
caus
presenc
peripher
blood
csf
csf
naa
consid
mani
diagnost
standard
care
discuss
lack
standard
fdaapprov
assay
made
implement
csf
naa
difficult
nonacadem
set
laboratori
offer
csf
naa
use
qualit
method
data
indic
role
quantit
csf
naa
differenti
nonspecif
presenc
viru
virusassoci
diseas
aid
prognosi
improv
patient
manag
monitor
antivir
therapi
quest
search
rapid
cheap
easi
perform
highli
sensit
specif
test
result
introduct
applic
variou
new
test
diagnosi
bacteri
mening
test
base
immunolog
principl
viz
counterimmunoelectrophoresi
latex
agglutin
test
coagglutin
radioimmunoassay
haemagglutin
inhibit
well
studi
immun
profil
cerebrospin
fluid
apart
certain
nonimmunolog
test
viz
limulu
amoebecyt
lysat
test
ga
liquid
chromatographi
nitroblu
tetrazolium
dye
reduct
test
also
evalu
make
laboratori
diagnosi
import
clinic
entiti
rapid
reliabl
ichhpujani
bhatia
tuberculin
skin
test
immunolog
diagnosi
mycobacterium
tuberculosi
infect
mani
limit
includ
confound
bacillu
bcg
vaccin
exposur
nontubercul
mycobacteria
tuberculosisspecif
antigen
absent
bcg
nontubercul
mycobacteria
identifi
mori
et
al
examin
use
two
antigen
whole
blood
ifngamma
assay
diagnost
test
tuberculosi
bcgvaccin
individu
enzymelink
immunoassay
diagnosi
tuberculosi
devis
use
shotgun
immunoexpress
librari
vector
dna
virul
tuberculosi
strain
shear
express
gener
shotgun
polypeptid
promis
mycobacteri
dna
cassett
subclon
express
glutathion
stransferas
gst
fusion
vector
strong
tac
promot
express
escherichia
coli
recombin
protein
use
elisa
differenti
bcgvaccin
healthi
subject
patient
activ
tuberculosi
prove
effect
detect
pulmonari
well
extrapulmonari
tuberculosi
overal
sensit
overal
specif
bisen
et
al
simpl
rapid
costeffect
glycolipid
antibodi
base
liposom
agglutin
assay
viz
tb
screen
test
diagnosi
patient
pulmonari
extrapulmonari
tuberculosi
sensit
specif
develop
tiwari
et
al
assay
clearli
differenti
healthi
control
bovi
bcgvaccin
subject
activ
tuberculosi
tbm
card
test
base
liposom
agglutin
test
develop
detect
glycolipid
antigen
tuberculosi
test
shown
effect
detect
glycolipid
antigen
tuberculosi
clinic
sampl
patient
activ
tb
low
ngml
analyt
sensit
clinic
sensit
specif
test
prove
highli
econom
rapid
simpl
instrument
free
test
seem
fairli
use
mass
test
varieti
biolog
specimen
cerebrospin
pleural
synovi
fluid
serum
tissu
biopsi
extract
patient
tubercul
mening
pulmonari
tb
extrapulmonari
tb
endem
countri
sensit
naa
detect
mtb
smearposit
respiratori
specimen
specif
wherea
sensit
specif
smearneg
specimen
respect
note
naa
mtb
replac
need
routin
mycobacteri
cultur
suscept
test
addit
direct
detect
mtb
techniqu
probebas
technolog
sequenc
analysi
appli
cultur
isol
decreas
time
identif
routin
biochem
analysi
rapid
identif
mtb
impact
patient
care
also
infect
control
due
increas
frequenc
isol
mycobacteri
speci
associ
immunocompromis
host
increas
incid
multidrug
resist
mtb
becom
imper
offer
accur
yet
rapid
diagnost
tool
detect
identif
mycobacteria
debat
exist
regard
gold
standard
laboratori
diagnosi
bordetella
pertussi
histor
cultur
plate
collect
patient
bedsid
ie
cough
plate
consid
refer
method
although
cultur
specif
sensit
suffer
partial
due
organ
fastidi
natur
primarili
highest
sensit
cultur
occur
patient
symptomat
naa
remain
posit
longer
therapi
cultur
naa
also
posit
longer
period
onset
symptom
therefor
naa
use
patient
present
later
ill
naa
test
allow
sameday
result
sinc
erythromycinresist
b
pertussi
still
rare
cultur
isol
rare
need
antimicrobi
suscept
test
multipl
studi
demonstr
signific
increas
detect
b
pertussi
compar
naa
cultur
report
pcrposit
cultureneg
sampl
rang
howev
due
potenti
fals
posit
fals
neg
result
b
pertussi
naa
procedur
strongli
recommend
result
consid
context
patient
clinic
present
clinic
inconsist
result
confirm
second
method
naa
also
use
bacteriolog
detect
antimicrobi
resist
sinc
antimicrobi
resist
multifactori
practic
limit
organ
result
interpret
confid
regard
genotyp
relationship
clinic
treatment
andor
infect
control
precaut
exampl
direct
detect
vancomycinresist
enterococcu
vre
methicillinresist
staphylococcu
aureu
mrsa
rectal
nare
surveil
cultur
respect
screen
patient
vre
mrsa
carriag
key
strategi
prevent
spread
organ
health
care
set
naa
technolog
reportedli
increas
vre
detect
addit
enterococci
confer
lowlevel
intrins
resist
thu
consid
true
vre
accur
rule
prevent
unnecessari
contact
precaut
contribut
hospit
save
naa
detect
mrsa
shown
equal
sensit
culturebas
method
advantag
offer
faster
turnaround
time
thu
impact
hospit
cost
save
howev
note
direct
specimen
test
mrsa
come
limit
often
includ
lower
posit
predict
valu
convent
method
recent
new
strain
mrsa
appear
associ
skin
soft
tissu
infect
outpati
call
communityassoci
mrsa
camrsa
increas
incid
camrsa
caus
overal
rate
mrsa
rise
therefor
becom
even
import
quickli
accur
identifi
resist
isol
incid
invas
fungal
infect
increas
consider
recent
year
mycetoma
chronic
granulomat
subcutan
infect
caus
either
actinomycet
bacteria
eumycet
fungi
diseas
endem
tropic
characteris
slow
progress
risk
bone
viscer
involv
notabl
advanc
improv
molecular
techniqu
speci
identif
carbapenem
oxazolidinon
triazol
emerg
promis
therapeut
option
access
drug
therapi
develop
countri
remain
limit
poor
avail
high
cost
ameen
arena
molecular
assay
use
pcrelisa
help
diagnosi
invas
fungal
infect
earli
stage
infect
clinic
manifest
badie
et
al
commerci
kit
molecular
detect
identif
infecti
pathogen
provid
degre
standard
eas
use
facilit
introduct
molecular
diagnost
clinic
microbiolog
laboratori
tabl
use
nucleic
acid
probe
identifi
cultur
organ
direct
detect
organ
clinic
materi
first
exposur
laboratori
commerci
avail
molecular
test
although
probe
test
still
wide
use
amplificationbas
method
increasingli
employ
diagnosi
identif
quantit
pathogen
character
antimicrobialdrug
resist
gene
commerci
amplif
kit
avail
pathogen
tabl
clinic
import
pathogen
requir
investigatordesign
homebrew
method
tabl
addit
molecular
strain
type
genotyp
proven
use
guid
therapeut
decis
certain
viral
pathogen
epidemiolog
investig
infect
control
laboratori
character
microbi
pathogen
biolog
genet
relat
frequent
use
investig
sever
differ
epidemiolog
type
method
appli
studi
microbi
pathogen
tabl
phenotyp
method
occasion
use
describ
epidemiolog
infecti
diseas
howev
variabl
slow
laborintens
much
use
epidemiolog
investig
newer
dnabas
type
method
elimin
limit
prefer
techniqu
epidemiolog
type
wide
use
molecular
type
method
includ
plasmid
profil
restrict
endonucleas
analysi
plasmid
genom
dna
southern
hybrid
analysi
use
specif
dna
probe
chromosom
dna
profil
use
either
pulsedfield
gel
electrophoresi
pfge
pcrbase
method
method
use
electr
field
separ
dna
fragment
whole
chromosom
plasmid
uniqu
pattern
fingerprint
visual
stain
ethidium
bromid
nucleic
acid
probe
hybrid
molecular
type
perform
determin
whether
differ
isol
give
differ
result
one
test
epidemiolog
relat
isol
share
dna
profil
fingerprint
wherea
sporad
epidemiolog
unrel
isol
distinctli
differ
pattern
isol
differ
patient
share
fingerprint
probabl
origin
clone
transmit
patient
patient
common
sourc
mechan
molecular
type
method
allow
investig
studi
relationship
colon
infect
isol
individu
patient
distinguish
contamin
infect
strain
document
nosocomi
transmiss
hospit
patient
evalu
reinfect
versu
relaps
patient
treat
infect
follow
spread
antimicrobialdrug
resist
strain
within
hospit
time
avail
dnabas
type
method
may
use
studi
nosocomi
infect
appli
context
care
epidemiolog
investig
contrast
even
power
sophist
type
method
use
indiscrimin
absenc
sound
epidemiolog
data
may
provid
conflict
confus
inform
molecular
test
infecti
diseas
includ
test
host
predisposit
diseas
screen
infect
colon
person
diagnosi
clinic
import
infect
monitor
cours
infect
spread
specif
pathogen
given
popul
often
assum
addit
improv
patient
care
major
financi
benefit
may
accru
molecular
test
test
reduc
use
less
sensit
specif
test
unnecessari
diagnost
procedur
therapi
nosocomi
infect
howev
inher
cost
molecular
test
method
coupl
variabl
inadequ
reimburs
thirdparti
payer
managedcar
organ
limit
introduct
test
clinic
diagnost
laboratori
molecular
diagnost
test
extrem
expens
direct
cost
vari
wide
depend
test
complex
sophist
inexpens
molecular
test
gener
kit
base
use
method
requir
littl
instrument
technologist
experi
dna
probe
method
detect
c
trachomati
n
gonorrhoea
exampl
lowcost
molecular
test
complex
molecular
test
resist
genotyp
often
high
labor
cost
requir
experienc
welltrain
technologist
although
sophist
test
may
requir
expens
equip
eg
dna
sequenc
reagent
advanc
autom
product
lessexpens
reagent
promis
decreas
cost
well
technician
time
major
obstacl
establish
molecular
diagnost
laboratori
often
consid
late
process
requir
licens
exist
pend
patent
test
select
bill
reimburs
molecular
screen
program
infecti
diseas
develop
detect
symptomat
asymptomat
diseas
individu
group
person
high
risk
immunocompromis
patient
attend
famili
plan
obstetr
clinic
screen
cmv
chlamydia
respect
likewis
blood
donor
screen
bloodborn
pathogen
financi
outcom
test
unknown
cost
must
balanc
benefit
earlier
diagnosi
treatment
societ
issu
diseas
epidemiolog
popul
manag
one
highli
tout
benefit
molecular
test
infecti
diseas
promis
earlier
detect
certain
pathogen
rapid
detect
tuberculosi
directli
clinic
specimen
pcr
amplificationbas
method
quit
like
costeffect
manag
tuberculosi
exampl
infecti
diseas
amen
molecular
diagnosi
manag
improv
technolog
includ
hsv
enceph
helicobact
pylori
infect
neuroborreliosi
caus
borrelia
burgdorferi
hsv
enceph
detect
hsv
cerebrospin
fluid
csf
direct
specif
therapi
elimin
test
includ
brain
biopsi
likewis
detect
h
pylori
gastric
fluid
direct
therapi
obviat
need
endoscopi
biopsi
pcr
detect
b
burgdorferi
csf
help
differenti
neuroborreliosi
chronic
neurolog
condit
chronic
fatigu
syndrom
discuss
earlier
molecular
test
may
use
predict
diseas
respons
specif
antimicrobi
therapi
detect
specif
resist
gene
mec
van
point
mutat
result
resist
proven
efficaci
manag
diseas
molecularbas
viral
load
test
becom
standard
practic
patient
chronic
hepat
aid
viral
load
test
genotyp
hcv
use
determin
use
expens
therapi
interferon
use
justifi
decis
extent
durat
therapi
aid
viral
load
determin
plu
resist
genotyp
use
select
among
variou
proteas
inhibitor
drug
avail
treatment
improv
patient
respons
decreas
incid
opportunist
infect
pharmacogenom
use
molecularbas
test
predict
respons
specif
therapi
monitor
respons
diseas
agent
administ
best
exampl
pharmacogenom
infecti
diseas
use
viral
load
resist
genotyp
select
monitor
antivir
therapi
aid
chronic
hepat
applic
improv
diseas
outcom
shorten
length
hospit
stay
reduc
advers
event
toxic
facilit
costeffect
therapi
avoid
unnecessari
expens
drug
optim
dose
time
elimin
ineffect
drug
molecular
strain
type
microorgan
well
recogn
essenti
compon
comprehens
infect
control
program
also
involv
infect
control
depart
infecti
diseas
divis
pharmaci
molecular
techniqu
establish
presenc
absenc
clonal
effect
track
spread
nosocomi
infect
streamlin
activ
infect
control
program
comprehens
infect
control
program
use
activ
surveil
infect
control
practition
clinic
microbiolog
laboratori
identifi
cluster
infect
common
microbi
phenotyp
speci
antimicrobi
suscept
profil
isol
character
laboratori
use
one
number
molecular
type
method
confirm
refut
clonal
field
molecular
infecti
diseas
test
grown
rapidli
diagnost
industri
kept
fill
void
independ
investig
turn
develop
userdefin
homebrew
molecular
detect
method
clinic
laboratori
implement
userdefin
naa
test
revolution
clinic
molecular
infecti
diseas
test
addit
commerciallyavail
nonfdaapprov
naa
assay
increasingli
becom
avail
analyt
specif
reagent
asr
though
reagent
necessari
amplif
reaction
purchas
commerci
assay
develop
verif
studi
must
perform
individu
laboratori
mani
case
compar
studi
userdefin
naa
procedur
includ
asr
limit
compar
valu
assay
institut
particularli
viral
load
monitor
restrict
applic
procedur
experienc
laboratori
without
consider
cost
molecular
infecti
diseas
diagnost
lab
develop
repres
institut
commit
cost
may
offset
analysi
hospitalwid
cost
save
employ
ie
shorter
hospit
stay
decreas
use
unncecessari
antibiot
cost
incur
stem
instrument
purchas
also
dedic
expert
staff
requir
test
sinc
mani
academ
medic
center
resort
implement
userdefin
assay
verif
valid
studi
substanti
requir
extens
resourc
includ
time
staff
expertis
studi
crucial
defin
perform
assay
determin
appropri
clinic
util
fda
diagnost
compani
major
molecular
infecti
diseas
laboratori
need
work
togeth
resolv
poor
standard
exist
laboratori
use
userdefin
assay
asr
applic
molecular
technolog
clinic
microbiolog
endless
challeng
also
abound
still
learn
mani
naa
result
mean
term
infecti
etiolog
use
molecular
technolog
detect
potenti
etiolog
agent
diseas
need
rememb
koch
postul
mere
presenc
organ
nucleic
acid
convinc
evid
diseas
causat
undoubtedli
addit
clinic
scientif
evid
need
make
claim
evid
lack
thereof
consid
interpret
molecular
infecti
diseas
result
though
still
much
learn
regard
appropri
applic
interpret
molecular
infecti
diseas
test
numer
excit
opportun
horizon
userdefin
assay
asr
allow
experienc
laboratori
offer
critic
diagnost
servic
yet
becom
avail
fda
clearanc
investig
refin
molecular
applic
infecti
diseas
test
diagnost
compani
market
applic
qualiti
control
govern
organ
standard
result
cost
associ
implement
decreas
reimburs
increas
molecular
infecti
diseas
test
avail
academ
medic
center
refer
laboratori
also
transit
commun
hospit
thu
global
impact
patient
care
